Have a feature idea you'd love to see implemented?
Let us know!
TBPH Theravance Biopharma Inc
Price (delayed)
$8.58
Market cap
$419.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$419.23M
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives
Highlights
TBPH's revenue is up by 21% year-on-year
The gross profit has grown by 21% YoY
Theravance Biopharma's EPS has shrunk by 108% YoY and by 7% QoQ
The net income has plunged by 105% YoY
Key stats
What are the main financial stats of TBPH
Market
Valuations
Earnings
Shares outstanding
48.92M
Market cap
$419.75M
Enterprise value
$419.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
6.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.76
Revenue
$62.02M
EBIT
-$35.72M
EBITDA
-$29.47M
Free cash flow
-$9.6M
Per share
Balance sheet
Liquidity
EPS
-$0.94
Free cash flow per share
-$0.2
Book value per share
$3.98
Revenue per share
$1.27
TBVPS
$7.43
Total assets
$362.03M
Total liabilities
$168.34M
Debt
$46.66M
Equity
$193.69M
Working capital
$96.36M
Debt to equity
0.24
Current ratio
5.2
Quick ratio
4.85
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
-47.5%
Gross margin
100%
Net margin
-73.6%
Operating margin
-67.6%
Return on assets
-11.9%
Return on equity
-21.3%
Return on invested capital
-10.1%
Return on capital employed
-10.5%
Return on sales
-57.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TBPH stock price
How has the Theravance Biopharma stock price performed over time
Intraday
-0.81%
1 week
-0.58%
1 month
6.45%
1 year
-7.74%
YTD
-23.67%
QTD
6.45%
Financial performance
How have Theravance Biopharma's revenue and profit performed over time
Revenue
$62.02M
Gross profit
$62.02M
Operating income
-$41.91M
Net income
-$45.65M
Gross margin
100%
Net margin
-73.6%
The net income has plunged by 105% YoY
Theravance Biopharma's net margin has shrunk by 104% YoY
Theravance Biopharma's operating margin has surged by 52% YoY
The operating income is up by 42% YoY
Growth
What is Theravance Biopharma's growth rate over time
Valuation
What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
2.15
P/S
6.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.76
Theravance Biopharma's EPS has shrunk by 108% YoY and by 7% QoQ
TBPH's equity is down by 31% year-on-year and by 5% since the previous quarter
The P/S is 49% lower than the 5-year quarterly average of 13.3 and 17% lower than the last 4 quarters average of 8.2
TBPH's revenue is up by 21% year-on-year
Efficiency
How efficient is Theravance Biopharma business performance
The ROE has plunged by 110% YoY and by 12% from the previous quarter
The company's return on assets has shrunk by 108% YoY and by 7% QoQ
The ROIC has plunged by 103% YoY and by 5% from the previous quarter
Theravance Biopharma's return on sales has shrunk by 103% YoY
Dividends
What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TBPH.
Financial health
How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 115% more than its total liabilities
The company's quick ratio fell by 35% YoY and by 9% QoQ
TBPH's current ratio is down by 34% year-on-year and by 9% since the previous quarter
Theravance Biopharma's debt is 76% lower than its equity
The debt to equity rose by 33% YoY and by 4.3% QoQ
TBPH's equity is down by 31% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.